ArticlePloS one2012
Biodegradable thermosensitive hydrogel for SAHA and DDP delivery: therapeutic effects on oral squamous cell carcinoma xenografts.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Nanotechnology-based drug delivery systems for treatment of oral cancer: a review.International journal of nanomedicine · 2014Pooled it
- Research Strategies and Methods of Hydrogels for Antitumor Drug Delivery.Biomedicines · 2025Review
- Advanced drug delivery systems for oral squamous cell carcinoma: a comprehensive review of nanotechnology-based and other innovative approaches.Frontiers in drug delivery · 2025Review
- Targeting the epigenome with advanced delivery strategies for epigenetic modulators.Bioengineering & translational medicine · 2025Review
- Developing functional hydrogels for treatment of oral diseases.Smart medicine · 2024Review
- Platinum-based drugs and hydrogel: a promising anti-tumor combination.Drug delivery · 2023Review
- Localized Drug Delivery Systems: An Update on Treatment Options for Head and Neck Squamous Cell Carcinomas.Pharmaceutics · 2023Review
- Developments on the Smart Hydrogel-Based Drug Delivery System for Oral Tumor Therapy.Gels (Basel, Switzerland) · 2022Review
- Current trends of targeted therapy for oral squamous cell carcinoma.Journal of cancer research and clinical oncology · 2022Review
- A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer.Nature communications · 2022Article
- Optimization and Evaluation of Poly(lactide-Pharmaceutics · 2020Article
- Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy.Frontiers in cell and developmental biology · 2020Review
- Research Progress and Prospect of Nanoplatforms for Treatment of Oral Cancer.Frontiers in pharmacology · 2020Review
- Controlled Drug Delivery Systems for Oral Cancer Treatment-Current Status and Future Perspectives.Pharmaceutics · 2019Review
- ING5-mediated antineuroblastoma effects of suberoylanilide hydroxamic acid.Cancer medicine · 2018Article
- Efficient inhibition of cervical cancer by dual drugs loaded in biodegradable thermosensitive hydrogel composites.Oncotarget · 2018Article
- The possibility of healing alveolar bone defects with simvastatin thermosensitive gel: in vitro/in vivo evaluation.Drug design, development and therapy · 2018Article
- Synthesis and Application of Injectable Bioorthogonal Dendrimer Hydrogels for Local Drug Delivery.ACS biomaterials science & engineering · 2017Article
- SAHA and/or MG132 reverse the aggressive phenotypes of glioma cells: An in vitro and vivo study.Oncotarget · 2017Article
- Antitumor activity of vorinostat-incorporated nanoparticles against human cholangiocarcinoma cells.Journal of nanobiotechnology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOSCC is one of the most common malignancies and numerous clinical agents currently applied in combinative chemotherapy. Here we reported a novel therapeutic strategy, SAHA and DDP-loaded PECE (SAHA-DDP/PECE), can improve the therapeutic effects of intratumorally chemotherapy on OSCC cell xenografts. OBJECTIVE/PURPOSE: The objective of this study was to evaluate the therapeutic efficacy of the SAHA-DDP/PECE in situ controlled drug delivery system on OSCC cell xenografts.
methodsA biodegradable and thermosensitive hydrogel was successfully developed to load SAHA and DDP. Tumor-beared mice were intratumorally administered with SAHA-DDP/PECE at 50 mg/kg (SAHA) +2 mg/kg (DDP) in 100 ul PECE hydrogel every two weeks, SAHA-DDP at 50 mg/kg(SAHA) +2 mg/kg(DDP) in NS, 2 mg/kg DDP solution, 50 mg/kg SAHA solution, equal volume of PECE hydrogel, or equal volume of NS on the same schedule, respectively. The antineoplastic actions of SAHA and DDP alone and in combination were evaluated using the determination of tumor volume, immunohistochemistry, western blot, and TUNEL analysis.
resultsThe hydrogel system was a free-flowing sol at 10 °C, become gel at body temperature, and could sustain more than 14 days in situ. SAHA-DDP/PECE was subsequently injected into tumor OSCC tumor-beared mice. The results demonstrated that such a strategy as this allows the carrier system to show a sustained release of SAHA and DDP in vivo, and could improved therapeutic effects compared with a simple additive therapeutic effect of SAHA and DDP on mouse model.
conclusionsOur research indicated that the novel SAHA-DDP/PECE system based on biodegradable PECE copolymer enhanced the therapeutic effects and could diminished the side effects of SAHA/DDP. The present work might be of great importance to the further exploration of the potential application of SAHA/DDP-hydrogel controlled drug release system in the treatment of OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.